Literature DB >> 35699442

Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.

Laura A Doorley1,2, Jeffrey M Rybak1, Elizabeth L Berkow2, Qing Zhang1, Joachim Morschhäuser3, P David Rogers1,2.   

Abstract

Candida parapsilosis is a common cause of invasive candidiasis worldwide and is the most commonly is7olated Candida species among pediatric and neonatal populations. Previous work has demonstrated that nonsynonymous mutations in the gene encoding the putative transcription factor CpMrr1 can influence fluconazole susceptibility. However, the direct contribution of these mutations and how they influence fluconazole resistance in clinical isolates are poorly understood. We identified 7 nonsynonymous CpMRR1 mutations in 12 isolates from within a collection of 35 fluconazole-resistant clinical isolates. The mutations leading to the A854V, R479K, and I283R substitutions were further examined and found to be activating mutations leading to increased fluconazole resistance. In addition to CpMDR1, we identified two other genes, one encoding a major facilitator superfamily (MFS) transporter (CpMDR1B, CPAR2_603010) and one encoding an ATP-binding cassette (ABC) transporter (CpCDR1B, CPAR2_304370), as being upregulated in isolates carrying CpMRR1-activating mutations. Overexpression of CpMDR1 in a susceptible strain and disruption in resistant clinical isolates that overexpress CpMDR1 had little to no effect on fluconazole susceptibility. Conversely, overexpression of either CpMDR1B or CpCDR1B increased resistance, and disruption in clinical isolates overexpressing these genes decreased fluconazole resistance. Our findings suggest that activating mutations in CpMRR1 represent important genetic determinants of fluconazole resistance in clinical isolates of C. parapsilosis, and unlike what is observed in Candida albicans, this is primarily driven by upregulation of both MFS (CpMdr1B) and ABC (CpCdr1B) transporters.

Entities:  

Keywords:  Candida parapsilosis; MRR1; fluconazole; resistance

Mesh:

Substances:

Year:  2022        PMID: 35699442      PMCID: PMC9295576          DOI: 10.1128/aac.00289-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  33 in total

1.  Loss of C-5 Sterol Desaturase Activity Results in Increased Resistance to Azole and Echinocandin Antifungals in a Clinical Isolate of Candida parapsilosis.

Authors:  Jeffrey M Rybak; C Michael Dickens; Josie E Parker; Kelly E Caudle; Kayihura Manigaba; Sarah G Whaley; Andrew T Nishimoto; Arturo Luna-Tapia; Sujoy Roy; Qing Zhang; Katherine S Barker; Glen E Palmer; Thomas R Sutter; Ramin Homayouni; Nathan P Wiederhold; Steven L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2.

Authors:  Alix T Coste; Mahir Karababa; Françoise Ischer; Jacques Bille; Dominique Sanglard
Journal:  Eukaryot Cell       Date:  2004-12

3.  Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system.

Authors:  Nina T Grossman; Cau D Pham; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

4.  Epidemiology and Molecular Basis of Resistance to Fluconazole Among Clinical Candida parapsilosis Isolates in Kuwait.

Authors:  Mohammad Asadzadeh; Suhail Ahmad; Noura Al-Sweih; Ziauddin Khan
Journal:  Microb Drug Resist       Date:  2017-03-29       Impact factor: 3.431

5.  Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans.

Authors:  Sabrina Schubert; Katherine S Barker; Sadri Znaidi; Sabrina Schneider; Franziska Dierolf; Nico Dunkel; Malika Aïd; Geneviève Boucher; P David Rogers; Martine Raymond; Joachim Morschhäuser
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans.

Authors:  Stephanie A Flowers; Katherine S Barker; Elizabeth L Berkow; Geoffrey Toner; Sean G Chadwick; Scott E Gygax; Joachim Morschhäuser; P David Rogers
Journal:  Eukaryot Cell       Date:  2012-08-24

7.  Trends in antifungal use in US hospitals, 2006-12.

Authors:  Snigdha Vallabhaneni; James Baggs; Sharon Tsay; Arjun R Srinivasan; John A Jernigan; Brendan R Jackson
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

Review 8.  Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species.

Authors:  Sarah G Whaley; Elizabeth L Berkow; Jeffrey M Rybak; Andrew T Nishimoto; Katherine S Barker; P David Rogers
Journal:  Front Microbiol       Date:  2017-01-12       Impact factor: 5.640

9.  Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016.

Authors:  Mitsuru Toda; Sabrina R Williams; Elizabeth L Berkow; Monica M Farley; Lee H Harrison; Lindsay Bonner; Kaytlynn M Marceaux; Rosemary Hollick; Alexia Y Zhang; William Schaffner; Shawn R Lockhart; Brendan R Jackson; Snigdha Vallabhaneni
Journal:  MMWR Surveill Summ       Date:  2019-09-27

10.  Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy.

Authors:  Li Zhang; Meng Xiao; Matthew R Watts; He Wang; Xin Fan; Fanrong Kong; Ying-Chun Xu
Journal:  BMC Infect Dis       Date:  2015-08-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.